4th Quarter - Report

INFECTIOUS DISEASES SOCIETY OF AMERICA for INFECTIOUS DISEASES SOCIETY OF AMERICA

Firm
Client
Income
—
Expenses
$160,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Creation of tax credits to incentivize R&D of new antibiotics for serious and life threatening drug-resistant infections (generally, no specific legislation); related new rapid diagnostic tests (generally, no specific legislation).

LobbyistCovered position, as disclosed
AMANDA JEZEK V.P. Public Policy & Government Relations
JONATHAN NURSE Government Relations Director

Contacted: SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Agency for Healthcare Research & Quality (AHRQ); Health Resources & Services Administration (HRSA)

Health Issues HCR

Infectious diseases (generally, no specific legislation); drug, diagnostics and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA)(generally, no specific legislation); Antibiotic Development to Advance Patient Treatment (ADAPT) Act (HR 2629); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act (HR 512); Promise for Antibiotics and Therapeutics for Health (PATH) Act (S.185); Preventing Antibiotic Resistance Act (PARA)(S.621)

LobbyistCovered position, as disclosed
AMANDA JEZEK V.P. Public Policy & Government Relations
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer
JONATHAN NURSE Government Relations Director

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Agency for Healthcare Research & Quality (AHRQ); SENATE; Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); Food & Drug Administration (FDA)

Bills named: S. 621 (114th), H.R. 512 (114th), H.R. 2629 (114th), S. 185 (114th)

Medicare/Medicaid MMM

Reimbursement for outpatient infusion therapy (generally, no specific legislation); physician payments (generally, no specific legislation); Medicaid and Medicare, including Medicare Prescription Drug Coverage (generally, no specific legislation); Average Sales Price (generally, no specific legislation); Competitive Acquisition Program (generally, no specific legislation); infection control (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); Healthcare Reform (generally, no specific legislation).

LobbyistCovered position, as disclosed
AMANDA JEZEK V.P. Public Policy & Government Relations
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer
JONATHAN NURSE Government Relations Director

Contacted: Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); SENATE; Health Resources & Services Administration (HRSA); Agency for Healthcare Research & Quality (AHRQ); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Budget/Appropriations BUD

Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.

LobbyistCovered position, as disclosed
AMANDA JEZEK V.P. Public Policy & Government Relations
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer
JONATHAN NURSE Government Relations Director

Contacted: Natl Institutes of Health (NIH); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS)

Medical/Disease Research/Clinical Labs MED

Medical liability (generally, no specific legislation); antimicrobial resistance research (generally, no specific legislation); infectious diseases product R&D (generally, no specific legislation); regulatory science (generally, no specific legislation); unnecessary regulatory burdens placed on medical research (generally, no specific legislation); laboratory developed tests (generally, no specific legislation); comparative effectiveness research (generally, no specific legislation); support for evidence-based decision making (generally, no specific legislation); point-of-care diagnostic tests (generally, no specific legislation); and organ transplant policy to allow HIV+ to HIV+ organ transplants (generally, no specific legislation).

LobbyistCovered position, as disclosed
AMANDA JEZEK V.P. Public Policy & Government Relations
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer
JONATHAN NURSE Government Relations Director

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); SENATE; Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.